GRI Bio Secures FDA Orphan Drug Designation

GRI Bio has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, GRI-0621 (Tazarotene), for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This designation is a significant regulatory milestone, potentially granting GRI Bio seven years of U.S. market exclusivity upon approval. The designation validates the drug's potential therapeutic value and provides a streamlined pathway for development and commercialization for patients with this rare lung disease.